# A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)

> **NCT05070390** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 18 (actual)

## Conditions studied

- Moderate Renal Impairment

## Interventions

- **DRUG:** Enlicitide Chloride

## Key facts

- **NCT ID:** NCT05070390
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-16
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-05-03
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05070390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05070390, "A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05070390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*